Actively Recruiting
Comparison of Body Composition Changes With Weight Loss Interventions
Led by Vanderbilt University Medical Center · Updated on 2025-10-21
60
Participants Needed
1
Research Sites
72 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is being done to compare the effects of a newer class of weight loss medications to weight loss surgery on the body's muscle, metabolism, and side effects over time. People with severe obesity often lose weight using either medications like GLP-1 receptor agonists (such as semaglutide or tirzepatide) or by having bariatric surgery, such as gastric bypass. While both approaches can lead to weight loss, they may affect the body in different ways. The investigators are inviting adult patients who are planning to either start one of these weight loss medications or undergo gastric bypass surgery to join this study. Participants will be asked to complete four body composition scans (called DXA scans) over the course of a year-at the beginning of the study and again at 3, 6, and 12 months. These scans will help us measure changes in fat and muscle. Participants will also complete surveys and provide information on side effects, such as nausea or fatigue, that may affect their eating or activity levels. The investigators' goal is to better understand how different weight loss treatments impact not just weight, but also muscle mass, energy levels, and side effects. This information may help doctors and patients choose the most appropriate treatment in the future.
CONDITIONS
Official Title
Comparison of Body Composition Changes With Weight Loss Interventions
Who Can Participate
Eligibility Criteria
You may qualify if you...
- BMI between 35 and 60
- Planning primary weight loss surgery (gastric bypass) or medical weight loss with GLP1 receptor agonists (Semaglutide or Tirzepatide)
- Age between 21 and 65 years
You will not qualify if you...
- Revisional gastric bypass surgery (e.g., sleeve to bypass)
- Less than 3 months of continuous GLP1 receptor agonist use
- Type 1 diabetes
- History of myocardial infarction
- Unstable angina or heart failure
- Stroke
- Solid organ transplantation
- Systemic glucocorticoid use in the prior 28 days
- Uncontrolled hypertension (systolic > 150 or diastolic > 90)
- Untreated hyperthyroidism
- Chronic kidney disease with estimated glomerular filtration rate less than 60
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
Actively Recruiting
Research Team
J
Jason M Samuels, MD
CONTACT
J
Jason Samuels
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here